Figure 1

PASI 90 % responders for subjects having a <PASI 90 at Week 16 and are administered mirikizumab 300 mg SC Q8W during Weeks 16-52 of the maintenance period




Figure 2

PASI 100 % responders for subjects that have a <PASI 90 at Week 16 and are administered mirikizumab 300 mg SC Q8W during Weeks 16-52 of the maintenance period




Figure 3

Figure 3a. PASI 75 Response Rates at Week 52 among Exposure-Naïve and Prior-Exposure Patient Groups, NRI




Figure 3b. PASI 90 Response Rates at Week 52 among Exposure-Naïve and Prior-Exposure Patient Groups, NRI




Figure 3c: PASI 100 Response Rates at Week 52 Among Exposure-Naïve and Prior-Exposure Patient Groups, NRI

